



Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma

Yuanyuan Ruan,^{1,2} Linlin Sun,^{1,2} Yuqing Hao,^{1,2} Lijing Wang,^{1,2} Jiejie Xu,^{1,2} Wen Zhang,^{3,4} Jianhui Xie,^{1,2} Liang Guo,^{1,2} Lei Zhou,^{1,2} Xiaojing Yun,^{1,2} Hongguang Zhu,^{3,5} Aiguo Shen,⁶ and Jianxin Gu^{1,2,3}

¹Key Laboratory of Glycoconjugate Research, Ministry of Public Health, and ²Department of Biochemistry and Molecular Biology, Shanghai Medical College of Fudan University, Shanghai, People's Republic of China. ³Institutes of Biomedical Sciences, Fudan University, Shanghai, People's Republic of China. ⁴Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, California, USA. ⁵Department of Pathology, Shanghai Medical College of Fudan University, Shanghai, People's Republic of China. ⁶Nantong Tumor Hospital, Nantong University, Nantong, People's Republic of China.

Coordinated translation initiation is coupled with cell cycle progression and cell growth, whereas excessive ribosome biogenesis and translation initiation often lead to tumor transformation and survival. Hepatocellular carcinoma (HCC) is among the most common and aggressive cancers worldwide and generally displays inherently high resistance to chemotherapeutic drugs. We found that RACK1, the receptor for activated C-kinase 1, was highly expressed in normal liver and frequently upregulated in HCC. Aberrant expression of RACK1 contributed to in vitro chemoresistance as well as in vivo tumor growth of HCC. These effects depended on ribosome localization of RACK1. Ribosomal RACK1 coupled with PKC β II to promote the phosphorylation of eukaryotic initiation factor 4E (eIF4E), which led to preferential translation of the potent factors involved in growth and survival. Inhibition of PKC β II or depletion of eIF4E abolished RACK1-mediated chemotherapy resistance of HCC in vitro. Our results imply that RACK1 may function as an internal factor involved in the growth and survival of HCC and suggest that targeting RACK1 may be an efficacious strategy for HCC treatment.

Introduction

Hepatocellular carcinoma (HCC) is among the most common and lethal cancers in the human population, ranked the fifth-most frequent neoplasm and the third-most common cause of cancer-related death worldwide (1). Though surveillance can lead to early diagnosis when the tumor might be resectable, most patients with HCC are diagnosed at advanced stages and can only receive palliative treatments. However, HCC generally displays inherent resistance to chemotherapeutic drugs, and systemic or selective intra-arterial administration of any chemotherapy agent, which has marginal antitumor activity and shows no benefit for survival, is not recommended in clinical practice (2–5).

Under normal circumstances, coordinated translation initiation is coupled with cell cycle progression and cell growth, whereas aberrant protein biosynthesis has been associated with tumor transformation and survival (6–8). In general, translation initiation, which is the rate-limiting step in protein synthesis, is tightly regulated by eukaryotic initiation factors (eIFs), including eIF2, which controls loading of the ternary complex on the 40S subunit, and eIF4E, which acts in the eIF4F complex and regulates binding of capped mRNA to 40S subunit (9–11). Increased eIF4E activity is associated with tumor formation and progression in several human malignancies, including leukemias, lymphomas, and cancers of the breast, colon, bladder, lung, prostate, and head and neck (12). While most cellular mRNAs require only minimal eIF4E to be efficiently translated, elevated eIF4E activity preferentially enhances translation of select mRNAs, many of which encode

potent growth and survival factors, such as cyclin D1, MYC, ODC, VEGF, Survivin (also known as BIRC5), and BCL-2 (12–14). Therapeutic repression of eIF4E expression induces apoptosis in tumor cell lines (14). Several drugs that suppress translation initiation by preventing eIF4F assembly (such as rapamycin) or blocking eIF4F activity (such as silvestrol), enhance the chemosensitivity in human and experimental cancers (15–19).


RACK1 was originally identified based on its ability to bind to the activated C kinase (PKC) isoform β II and is highly conserved among all eukaryotic species (20, 21). As a member of the Trp-Asp (WD) repeat protein family, it serves as a scaffold protein for many kinases and receptors and plays a pivotal role in a wide range of biological responses, including signal transduction and immune response as well as cell growth, migration, and differentiation (21). Recent studies have shown that RACK1 is a component of the 40S subunit of ribosome and present in both ribosome- and nonribosome-bound form (22–24). RACK1 is found to be upregulated in several kinds of tumors and considered as an excellent marker of oral squamous carcinoma, breast cancer, and pulmonary adenocarcinomas (25–29). Herein, we demonstrate that RACK1 is highly expressed in normal liver and frequently upregulated in HCC and that the ribosome localization is essential for RACK1-mediated in vitro chemoresistance and in vivo growth of HCC. Our results suggest that ribosomal RACK1 might function as an internal factor contributing to the growth and survival of HCC and that targeting RACK1 may be an efficacious strategy for HCC treatment.

Results

RACK1 is highly expressed in normal liver and frequently upregulated in HCC. RACK1 is a classic scaffold protein ubiquitously expressed

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: *J Clin Invest.* doi:10.1172/JCI58488.

**Figure 1**

RACK1 is preferentially expressed in normal liver and frequently upregulated in HCC. **(A)** Assessment of *RACK1* transcripts in a variety of normal human tissues. Total RNA was extracted from frozen fresh normal tissues, and quantitative real-time PCR was performed to assess *RACK1* transcripts, with β -actin mRNA as the internal control. Numbers listed are mean of each group. **(B)** Expression of *RACK1* in an immortalized liver cell line and HCC cell lines. **(C)** Expression of *RACK1* in paired liver tissue samples. N, adjacent nontumor sections; T, tumor sections. **(D)** mRNA levels of *RACK1* in paired liver tissue samples. Total RNA was extracted from paired liver tissue samples, and *RACK1* mRNA levels were detected by quantitative real-time PCR, with β -actin as internal control. **(E)** Expression of *RACK1* in HCC samples at different stages. *RACK1* expression was detected by immunohistochemistry in 162 HCC samples. In **B** and **C**, numbers represent relative expression of *RACK1*, which was quantified by comparing it with GAPDH. Original magnification, $\times 400$; scale bars: 20 μ m.


in the tissues of higher mammals and humans (21). We first examined the expression pattern of *RACK1* mRNA in various normal human tissues. As shown in Figure 1A, the highest mRNA level of *RACK1* was detected in normal liver. Western blot analysis of the tissues of adult mice also confirmed the highest protein level of *RACK1* in liver (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI58488DS1). These results suggest that, while ubiquitously distributed in the tissues of mammals, *RACK1* is highly expressed in the liver.

To understand whether *RACK1* was involved in the hepatocarcinogenesis, we first examined the expression of *RACK1* in HCC cell lines (HepG2, Huh7, Hep3B, PLC/PRF/5, BEL-7402, BEL-7404, and SK-Hep1) and the immortalized liver cell line (L02). The endogenous expression of *RACK1* in HCC cell lines was much higher than that in the L02 cell line (Figure 1B). Moreover, the expression of *RACK1* was higher in HCC samples compared with that in their adjacent nontumor tissues (Figure 1C). Quantitative real-time PCR also confirmed the increased mRNA levels of *RACK1* in most HCC cases (Figure 1D). These results suggest that *RACK1* is involved in the tumorigenesis of HCC.

To further determine the role of *RACK1* in the development of HCC, *RACK1* expression was detected in HCC cases at different

TNM stages (Supplemental Table 1). As shown in Figure 1E and Supplemental Table 2, *RACK1* expression was well correlated with the clinical progression of HCC ($P < 0.001$). Moreover, the protein level of *RACK1* was strongly related to the expression of Ki67 and the serum level of AFP ($P < 0.001$ and $P = 0.002$, respectively) as well as the poor prognosis of patients with HCC ($P < 0.001$) (Supplemental Tables 3 and 4 and Supplemental Figure 2). These results indicate that *RACK1* is frequently upregulated in HCC and suggest that *RACK1* may contribute to the tumorigenesis and progression of HCC.

Ribosomal RACK1 modulates the chemosensitivity of HCC in vitro. Since the antiapoptotic effect of *RACK1* has been characterized in several kinds of tumors, including breast cancer (30) and melanoma (31), we next examined the role of *RACK1* in the chemosensitivity of HCC in vitro. Overexpression of wild-type *RACK1* significantly inhibited doxorubicin-induced apoptosis in HepG2 (p53 wild-type), Huh7 (p53-mutated), and Hep3B (p53-null) cells, while depletion of *RACK1* enhanced the sensitivity to doxorubicin-induced apoptosis (Figure 2, A and B). Similar results were also observed in CDDP- and 5-FU-treated cells (data not shown). Moreover, overexpression of wild-type *RACK1* showed little effect on doxorubicin-induced transcriptional activity of p53 in HepG2 cells (Supplemental Figure 3). These results imply that *RACK1*

**Figure 2**

Ribosomal RACK1 contributes to the chemotherapy resistance of HCC in vitro. **(A)** Overexpression of RACK1 enhances the doxorubicin (Dox) resistance of HCC cell lines. Twenty-four hours after transfection with vector or wild-type RACK1, HepG2 (100 μ g/ml), Huh7 (20 μ g/ml), and Hep3B (50 μ g/ml) cells were treated with doxorubicin for indicated times. Cellular apoptosis was determined by annexin V staining. **(B)** Depletion of RACK1 sensitizes HCC cells to doxorubicin-induced apoptosis. Seventy-two hours after transfection with shLuc or shRACK1, cells were treated with doxorubicin for another 24 hours as in **A**. Numbers represent relative expression of RACK1, which was quantified by comparing it with GAPDH. **(C)** The ribosome localization of RACK1 is required for doxorubicin resistance of HCC. Twenty-four hours after transfection, Huh7 cells were treated with doxorubicin (20 μ g/ml) for another 24 hours. **(D)** The DE mutant sensitizes Huh7 cells to doxorubicin-induced apoptosis. Huh7 cells were transiently transfected with increasing doses of wild-type RACK1 or the DE mutant and treated as in **C**. **(E)** Wild-type RACK1, but not the DE mutant, restores the chemoresistance of RACK1-depleted HCC cells. HCC cells expressing shRACK1 were supertransfected with the constructs as indicated and treated with doxorubicin as in **A** for 24 hours. All assays were performed in triplicate.




Figure 3

Ribosomal RACK1 modulates tumor growth of HCC in vivo. (A and B) RACK1 depletion inhibited tumor growth in vivo. Xenografts were generated using Huh7 cells. (A) Two weeks later, retroviruses carrying shRNA and doxorubicin were delivered by intratumoral injection. Tumor volume was measured at indicated time points. (B) Tumor weight was measured on the day of harvest, after excision of the tumor from the euthanized mouse. (C–F) Ribosomal RACK1 modulates tumor growth in vivo. Xenografts were generated using Huh7 cells stably expressing empty vector, wild-type RACK1, or the DE mutant. Two weeks later, doxorubicin was given by intratumoral injection. In C and D, tumor volume and weight were measured as in A and B. In E and F, TUNEL assay was performed to detect apoptosis. Statistical significance was determined using 1-way or 2-way repeated-measures ANOVA. Original magnification, $\times 200$; scale bars: 200 μ m.

modulates the chemosensitivity of HCC in a p53-independent manner.

Several reports have implicated RACK1 in ways that are related to apoptosis resistance, such as BimEL degradation (30) and JNK activation (31). To understand how RACK1 modulates the chemosensitivity in HCC cells, wild-type RACK1 as well as several mutants with functional defects that have been described previously (32–35), were transfected into Huh7 cells. Interestingly, the nonribosome-binding mutant of RACK1 (the R36D/K38E mutant [DE mutant]) conversely sensitized Huh7 cells to doxorubicin-induced apoptosis, while the other mutants, including Y302F (β 1 integrin binding), Y52F (FAK activation), and Y228F/Y246F (Src activation), still promoted the chemotherapy resistance of HCC cells (Figure 2, C and D, and Supplemental Figure 4, A and B). Moreover, supertransfection of rescue wild-type RACK1, but not the DE mutant, restored the resistance to doxorubicin in RACK1-depleted cells (Figure 2E). These results imply that ribosomal localization is essential for RACK1-mediated chemotherapy resistance in vitro.

Ribosomal RACK1 modulates the tumor growth of HCC in vivo. We next determined the effects of RACK1 on the xenograft formation of HCC in vivo. Depletion of RACK1 alone inhibited xenograft development and induced significant suppression of tumor growth in combination with doxorubicin (Figure 3, A and B, and Sup-




Figure 4

Ribosomal RACK1 enhances global translation and the phosphorylation of eIF4E in a PKCβII-dependent manner. (A) Ribosomal RACK1 promotes de novo protein synthesis. The rate of [³⁵S]-methionine (35S-Met) incorporation was assessed relative to that of cells transfected with empty vector. (B) RACK1 is required for efficient translation. (C) RACK1 stimulates translation requiring PKCβII activity. Transfected Huh7 cells were incubated with CGP53353 (5 μM) or LY333531 (50 nM) for 1 hour. (D) Functional association with PKCβII is required for RACK1-stimulated translation. Intracellular delivery of TAT peptides was conducted as described in the Methods. (E) Ribosomal RACK1 enriches PKCβII with poly(A) mRNA. Huh7 cells were transfected as indicated, followed by oligo-dT pull-down assay. (F) The effect of ribosomal RACK1 on the phosphorylation of eIF2α and eIF4E. (G) PKCβII activity is required for RACK1-mediated phosphorylation of eIF4E. Huh7 cells were transfected and treated as in C. (H) RACK1/PKCβII interaction is required for RACK1-mediated phosphorylation of eIF4E. Huh7 cells were transfected and treated as in D. In A–D, assays were performed in quadruplicate ($n = 4$). In E–H, numbers represent relative expression of PKCβII, p-eIF2α (S51), or p-eIF4E (S209), which was quantified by comparing with GAPDH.

plemental Figure 5). To examine the effect of ribosomal RACK1 on tumor growth in vivo, xenografts were also generated using HCC cells stably transfected with wild-type RACK1 or the DE mutant. Overexpression of wild-type RACK1 promoted tumor growth in nude mice; however, the DE mutant failed to promote the generation of xenografts and showed more inhibitory effect on tumor growth upon doxorubicin treatment (Figure 3, C and D, and Supplemental Figure 4C). TUNEL staining revealed that under doxorubicin challenge, xenografts overexpressing the DE mutant displayed the highest rate of cellular apoptosis (Figure 3, E and F). Taken together, these results imply that ribosomal RACK1 modulates the tumor growth of HCC in vivo.

Ribosomal RACK1 modulates the rate of translation through PKCβII. Ribosomal RACK1 is a component of the 40S small subunit involved in the regulation of translation initiation (36–38). To explore the potency of ribosome-associated RACK1 on translation regulation in HCC, metabolic labeling studies were carried out. Overexpression of wild-type RACK1 promoted [³⁵S]-methionine incorporation, whereas DE mutant overexpression or RACK1 depletion partly inhibited de novo protein synthesis (Figure 4, A and B). The effect of ribosomal RACK1 on cap- and IRES-mediated translation was further assessed by using the bicistronic reporter pcDNA/Fluc/IRES/Rluc construct that we previously described (Supplemental Figure 6A and ref. 39). Introduction of wild-type




Figure 5 Ribosomal RACK1/PKCβII complex acts on eIF4E. (**A** and **B**) Polysome profiling and association of RACK1 and PKCβII with ribosomes in Huh7 cells. The asterisk indicates a nonspecific band. (**C**) Ribosomal association between eIF4E and RACK1. Purified ribosomes were digested with RNase and subjected to immunoprecipitation. Con, control. (**D**) RACK1 associates with eIF4F complex. (**E**) In vitro association between eIF4E and RACK1. (**F**) Ribosome localization is required for eIF4E and RACK1 association. Cell lysates of transfected Huh7 cells were applied to immunoprecipitation assay. (**G**) eIF4E is phosphorylated in vitro by PKCβII. (**H**) RACK1/PKCβII complex acts on eIF4E. In vitro phosphorylation assay was performed as described in the Supplemental Methods. (**I**) PKCβII restores eIF4E phosphorylation in *Mnk1*^{-/-} *Mnk2*^{-/-} MEFs. *Mnk1*^{-/-} *Mnk2*^{-/-} MEFs were transfected with PKCβII and treated with or without TPA (100 nM) for 1 hour. (**J**) Effect of ribosomal RACK1 on PKCβII-mediated eIF4E phosphorylation. *Mnk1*^{-/-} *Mnk2*^{-/-} MEFs were transfected with PKCβII, along with or without wild-type RACK1 or the DE mutant. (**K**) Effect of MNK inhibition on RACK1-mediated eIF4E phosphorylation. Transfected Huh7 cells were treated with CGP53353 (5 μM) and/or CGP57380 (10 μM). In **H–K**, numbers represent relative expression of p-eIF4E (S209), which was quantified by comparing with GAPDH (**I–K**).





Figure 6
Ribosomal RACK1 preferentially promotes the translation of potent growth and survival factors. **(A)** The effect of RACK1 on the expression of cyclin D1, MYC, Survivin, and BCL-2. **(B)** The effect of RACK1 on de novo protein synthesis of cyclin D1, MYC, Survivin, and BCL-2. After [³⁵S]-methionine labeling, cell extracts of Huh7 cells with equal CPM were subjected to immunoprecipitation. **(C)** The effect of RACK1 on the distribution of cyclin D1, MYC, Survivin, and BCL2 mRNAs in the polysomes. Huh7 cells were transfected as indicated, and cell lysates were applied to polysome profiling, followed by real-time PCR analysis. SP, a pool of subpolysome fractions containing 40S, 60S, and 80S ribosomes. In **A** and **B**, numbers represent relative expression of cyclin D1, MYC, Survivin, or BCL-2, which was quantified by comparing with GAPDH or β-actin. In **C**, the data shown are representative of 3 independent experiments.

RACK1 increased activities of both Firefly (cap dependent) and Renilla luciferase (ECMV IRES mediated), while DE mutant transfection or RACK1 depletion showed the opposite effect (Supplemental Figure 6, B–E). These results suggest that ribosomal RACK1, which possibly targets both cap- and IRES-mediated translation, contributes to translational regulation in HCC cells.

We next determined whether RACK1 stimulated translation through PKCβII, the known signaling molecule with which RACK1 interacts on ribosome (40). Administration of selective PKCβII inhibitor CGP53353 or PKCβ inhibitor LY333531 attenuated RACK1-mediated translation enhancement (Figure 4C). Moreover, delivery of recombinant peptide, which mimics

**Figure 7**

Ribosomal RACK1 preferentially promotes the translation of potent growth and survival factors. **(A)** Schematic diagram of SV40-based monocistronic constructs. **(B)** The effect of RACK1 on the translational activity of the 5'-UTR of cyclin D1, MYC, Survivin, and BCL-2. The relative luciferase activities of empty vector were normalized to 1. **(C)** Correlation of RACK1 with the expression of cyclin D1, MYC, Survivin, and BCL-2 in HCC cases. The expression profiles of cyclin D1, MYC, Survivin, and BCL-2 were examined by immunohistochemistry, quantified, and applied to Pearson's correlation analysis. In **B**, assays were performed in triplicate.

the RACK1 binding site and inhibits the interaction of RACK1 to PKC β II, also suppressed RACK1-stimulated translation (Figure 4D). These results suggest that RACK1 modulates translation in a PKC β II-dependent manner.


RACK1 binds to PKC β II with high affinity and is recognized as a shuttling protein that moves PKC β II from one intracellular site to another (41). To explore whether RACK1 stimulated translation by recruiting PKC β II to ribosome, oligo-dT pull-down assay was performed. Overexpression of wild-type RACK1 induced more enrichment of PKC β II with poly(A) mRNA, whereas overexpression of the DE mutant suppressed PKC β II enrichment, probably by competing with endogenous RACK1 in binding with PKC β II (Figure 4E and Supplemental Figure 7A). These results suggest that ribosomal RACK1 contributes to the recruitment of PKC β II to ribosome in HCC.

Ribosomal RACK1 modulates the phosphorylation of eIF4E through PKC β II. We next examined the effect of RACK1 on the rate-limiting factors of translation, whose activities play a central role in controlling translation initiation. Wild-type RACK1 promoted the phosphorylation of eIF4E on serine 209, whereas the DE mutant suppressed eIF4E phosphorylation (Figure 4F and Supplemental Figure 7B). Both RACK1 constructs showed little effect on the phosphorylation of eIF2 α (Figure 4F and Supplemental Figure 7B). Overexpression of RACK1 mutants (Y302F, Y52F, and Y228F/Y246F) also stimulated the PKC β II recruitment and eIF4E phosphorylation, further demonstrating the critical role of ribosomal RACK1 on eIF4E activation (Supplemental Figure 7C). Inhibiting PKC β II or abolishing the RACK1/PKC β II interaction suppressed

the regulatory effect of wild-type RACK1 on eIF4E phosphorylation, suggesting that PKC β II is required for RACK1-stimulated activity of eIF4E (Figure 4, G and H, and Supplemental Figure 7D). Moreover, overexpression of wild-type RACK1 stimulated the phosphorylation of eIF6 (36), a target of RACK1/PKC β II complex on ribosome, whereas the DE mutant suppressed eIF6 phosphorylation (Supplemental Figure 8).

Ribosomal RACK1/PKC β II complex associates with eIF4E. To understand how ribosomal RACK1/PKC β II complex modulated the activity of eIF4E, we first examined its effect on phosphorylation of MAP kinase-interacting serine/threonine kinase 1 (MNK1) and 4E-BP1, which are involved in the regulation of eIF4E phosphorylation and eIF4F formation, respectively (42, 43). However, inhibition of PKC β II or overexpression of RACK1 showed little effect on MNK1 or 4E-BP1 phosphorylation (Supplemental Figure 9).

We next examined whether ribosomal RACK1/PKC β II complex acted on eIF4E. Ribosome profiling confirmed the association of RACK1 with ribosomes and polysomes, while PKC β II was detected in 40S, 60S, and 80S ribosomes but not in polysomes, suggesting a role of ribosomal RACK1/PKC β II complex in the regulation of translation initiation (Figure 5, A and B). To explore whether ribosomal RACK1 coupled with eIF4E to allow the regulation of its phosphorylation, ribosomes were purified to perform coimmunoprecipitation. Results demonstrated that eIF4E, as well as eIF4G and PKC β II, was detected in the immunoprecipitates of RACK1 (Figure 5C). Affinity chromatography performed using the m⁷GDP Sepharose also confirmed that RACK1 associated with eIF4F complex (Figure 5D). GST pull-down assay further revealed



**Figure 8**

RACK1 promotes the in vitro chemotherapy resistance of HCC in a PKC β II- and eIF4E-dependent manner. (**A** and **B**) RACK1 promotes the expression of Survivin and BCL-2 in a PKC β II- and eIF4E-dependent manner. Huh7 cells were treated with (**A**) 5 μ M CGP53353 for 24 hours or (**B**) siEIF4E for 72 hours and then cell lysates were applied to Western blot analysis. In **A** and **B**, numbers represent relative expression of Survivin or BCL-2, which was quantified by comparing with GAPDH. (**C** and **D**) RACK1 promotes the right shift of Survivin and BCL2 mRNA in a PKC β II- and eIF4E-dependent manner. Huh7 cells were treated as in **A** or **B** and applied to polysome profiling, followed by real-time PCR analysis. (**E** and **F**) RACK1 preferentially upregulates the 5'-UTR activities of Survivin and BCL2 mRNAs in a PKC β II- and eIF4E-dependent manner. Huh7 cells were transfected and treated as in **A** or **B**, followed by luciferase assay. Relative luciferase activities were calculated by Survivin or BCL-2 compared with β -actin, and the ratio of empty vector was normalized to 1. (**G–J**) Huh7 cells were pre-treated with or without (**G**) CGP53353 (1 μ M), (**I**) cycloheximide (CHX) (50 nM), or (**J**) rapamycin (rapa) (10 nM) for 24 hours or (**H**) siEIF4E for 48 hours. Then cells were treated with doxorubicin (20 μ g/ml) for another 24 hours, collected, and applied to annexin V staining. In **C** and **D**, the data shown are representative of 3 independent experiments. In **E–J**, assays were performed in triplicate.

the direct interaction between RACK1 and eIF4E in vitro (Figure 5E). However, the DE mutant of RACK1 failed to bind to eIF4E in vivo, but not in vitro, suggesting that ribosomal localization is required for RACK1 to associate with eIF4E (Figure 5F and Supplemental Figure 10A).

We also examined the interface for RACK1 and eIF4E association. A competitive binding assay performed using the eIF4G peptides demonstrated that RACK1 and eIF4G do not compete for binding to eIF4E (Supplemental Figure 10B). Mutation analysis of the conserved residues localized within the dorsal surface of eIF4E revealed that the binding interface of eIF4E for RACK1 was possibly localized at the end of helix 2 (G139, E140, and D143) (Supplemental Figure 10C and ref. 44). GST pull-down assay performed using the truncated form of RACK1 also demonstrated that the WD repeats 5–7 were involved in the interaction with eIF4E (Supplemental Figure 10D). Since the WD repeat 5 of ribosomal RACK1 is largely obscured by ribosome proteins (45), the binding surface of RACK1 for eIF4E was possibly localized within WD repeats 6 and 7.

RACK1/PKC β II complex acts on eIF4E. We next detected whether RACK1/PKC β II complex acted on eIF4E. In vitro phosphorylation assay suggested that PKC β II directly phosphorylated eIF4E on serine 209 and RACK1 promoted PKC β II-mediated eIF4E phosphorylation in dose-dependent manner (Figure 5, G and H).

To understand whether eIF4E was a physiological substrate of PKC β II in vivo, we examined the effect of PKC β II on the phosphorylation of eIF4E in MNK1/2 double-knockout mouse embryo fibroblasts (MEFs), which was reported to show no phosphorylation of eIF4E (46). Transfection of wild-type PKC β II restored eIF4E phosphorylation, and this effect was enhanced upon tissue-type plasminogen activator (TPA) treatment (Figure 5I). Moreover, introduction of wild-type RACK1 moderately enhanced PKC β II-mediated eIF4E phosphorylation, while a contrary effect was observed in the DE mutant-transfected cells (Figure 5J).

We also examined the effect of MNK inhibition on RACK1-induced eIF4E phosphorylation in HCC. Treatment with the MNK inhibitor CGP57380, though it substantially suppressed the basal level of eIF4E phosphorylation in control cells, did not abol-

ish RACK1-induced eIF4E phosphorylation (Figure 5K). Moreover, inhibition of MNK and PKC β II synergistically abrogated the eIF4E phosphorylation, both in normal and RACK1-transfected Huh7 cells (Figure 5K). These results suggest that RACK1 stimulates eIF4E phosphorylation in MNK-independent manner and that MNK and PKC β II are both involved in the regulation of eIF4E phosphorylation in vivo.

Ribosomal RACK1 preferentially promotes the translation of potent growth and survival factors. While most cellular mRNAs require only minimal eIF4E to be efficiently translated, elevated eIF4E activity preferentially enhances translation of select mRNAs with lengthy G + C-rich 5'-UTRs, many of which encode potent growth and survival factors, such as cyclin D1, MYC, Survivin, and BCL-2 (12–14). Western blot analysis also revealed the upregulation of cyclin D1, MYC, Survivin, and BCL-2 induced by wild-type RACK1, whereas contrary results were observed in the DE mutant-transfected or RACK1-depleted cells (Figure 6A). Real-time PCR showed no statistically significant changes in cyclin D1, MYC, Survivin, and BCL2 mRNA levels in cells transfected with either construct (Supplemental Figure 11). To understand whether RACK1 modulated their protein expression at translational level, [35 S]-methionine incorporation assay was performed. Consistent with the alteration of protein expression, transfection of wild-type RACK1 upregulated the de novo protein level of cyclin D1, MYC, Survivin, and BCL-2, while transfection of the DE mutant or depletion of RACK1 attenuated their protein synthesis, as compared with that of β -actin (Figure 6B). Polysome profiling also showed that transfection of wild-type RACK1 induced more right shift of cyclin D1, MYC, Survivin, and BCL2 mRNAs from light polysomes to heavier polysomes, in comparison with that of β -actin mRNA (Figure 6C). In contrast, the distribution of cyclin D1, MYC, Survivin, and BCL2 mRNAs in the DE mutant-transfected or RACK1-depleted cells remarkably changed toward the gradient's fractions containing lighter polysomes, as compared with that of β -actin mRNA (Figure 6C).

To further evaluate the effect of ribosomal RACK1 on the 5'-UTR activity of select mRNAs, SV40-based monocistronic constructs were generated with the mRNAs' 5'-UTR to drive the translation of luciferase (Figure 7A). Overexpression of wild-type RACK1 induced more increases in the 5'-UTR activities of cyclin D1, MYC, Survivin, and BCL-2 compared with those of β -actin (Figure 7B), while, in contrast, a more inhibitory effect was observed upon transfection of RACK1 DE or shRACK1. Similar results were also observed in 7402 and PLC/PRF/5 HCC cell lines (Supplemental Figure 12). Together, these results suggest that, though ribosomal RACK1 is involved in regulation of global protein synthesis, it preferentially promotes the translation of potent growth and survival factors.

We also examined the correlation of RACK1 protein level with the expression of cyclin D1, MYC, Survivin, and BCL-2 in clinical HCC samples. As shown in Figure 7C, the protein level of RACK1 was statistically significantly correlated with the expression of cyclin D1, MYC, Survivin, and BCL-2. Taken together, these results suggest that ribosomal RACK1 may contribute to the growth and survival of tumor cells in HCC cases.

RACK1 promotes the chemoresistance of HCC in vitro in a PKC β II- and eIF4E-dependent manner. Since RACK1 synergized with PKC β II to modulate the phosphorylation of eIF4E, which is the key regulator of the translation of several potent survival factors, we next examined whether PKC β II and eIF4E were involved in RACK1-induced expression of survival factors in HCC cells. As shown in Figure 8, A and B, inhibition of PKC β II by CGP53353, or deple-



tion of eIF4E by siRNA specifically targeting eIF4E (sieIF4E), substantially blocked RACK1-induced upregulation of Survivin and BCL-2. Real-time PCR analysis showed no statistically significant changes in Survivin and *BCL2* mRNA levels in CGP53353- or sieIF4E-treated cells (data not shown). Polysome profiling further confirmed that CGP53353 or sieIF4E treatment substantially suppressed the right shift of Survivin and *BCL2* mRNAs from light polysomes to heavier polysomes induced by wild-type RACK1, while the distribution pattern of β -actin mRNA in polysomes was little or moderately affected (Figure 8, C and D). Moreover, luciferase assay also revealed that the preferential regulatory effect of wild-type RACK1 on the 5'-UTR activities of Survivin and *BCL2* mRNA was remarkably inhibited under CGP53353 or sieIF4E treatment, as compared with that of β -actin mRNA (Figure 8, E and F). These results suggest that RACK1 modulates the expression and translation of survival factors Survivin and BCL-2 in a PKC β II- and eIF4E-dependent manner.

We also examined whether PKC β II and eIF4E were involved in RACK1-mediated chemotherapy resistance in HCC in vitro. As shown in Figure 8, G and H, inhibition of PKC β II, or depletion of eIF4E, attenuated RACK1-mediated doxorubicin resistance. In addition, administration of cycloheximide, an inhibitor of translation elongation, or rapamycin, an inhibitor of cap-dependent translation, also abolished RACK1-mediated chemoresistance in vitro (Figure 8, I and J). It is consistent with previous reports that inhibiting translation can modulate the response of transformed cells to chemotherapeutic drugs (16–19, 47, 48). Taken together, these results imply that translational stimulation is involved in the drug resistance of HCC mediated by RACK1 in vitro and that RACK1 promotes the survival of HCC in a PKC β II- and eIF4E-dependent manner.

Discussion

HCC is a major health problem worldwide, with more than 500,000 new cases currently diagnosed yearly, and our previous investigations have elucidated possible mechanisms for HBV-associated hepatocarcinogenesis (49–51). We herein demonstrate that RACK1, a scaffold protein highly expressed in normal liver and frequently upregulated in HCC, contributes to the in vitro chemoresistance and in vivo growth of HCC and preferential translation of potent growth and survival factors. Our data support the fact that normal liver cells display a high rate of protein synthesis and mitosis and imply that the robust machinery of translation in normal liver may potentiate the growth and survival of HCC.

Translational control plays a crucial role in cancer development and progression, directing both global protein synthesis and selective translation of specific mRNAs that promote tumor survival and growth (6, 7). Altered levels and activities of translation initiation factors, which contribute to aberrant translational control, have been reported in a wide range of cancers (7). In this study, we observed that RACK1, which was involved in the regulation of eIF4E phosphorylation through PKC β II, was frequently upregulated in HCC. However, we did not detect remarkable expression alteration of the translation initiation factors (eIF2 α , eIF3, eIF4A, eIF4E, and eIF6) in our clinical samples, suggesting that translational control of cancer is multifaceted and may be unique to different types of cancers (our unpublished observations). Previous results as well as our results suggest eIF6 and eIF4E as the substrates of PKC β II (36); however, since the ribosomal position of RACK1 shows that the WD repeats responsible

for receptor/kinase binding are exposed to the solvent (40), other ribosomal substrates of RACK1/PKC β II complex may exist.

Though RACK1 participates in multiple biological processes, the role of ribosome-associated RACK1 has not been extensively defined. A previous report suggested that ribosomal RACK1/PKC β II phosphorylated eIF6 to induce its release from 60S subunit and allow 80S ribosome assembly (36). Recent studies demonstrate that ribosomal RACK1 is a component of stress granules and responsible for stress-mediated chemotherapy resistance (35, 52). Interestingly, many mRNAs that contain IRESs are sensitive to stress and encode proteins critical to cell growth, differentiation, and survival, suggesting that IRES-mediated translation provides means for selective translation of specific mRNAs and allows the regulation of cell death and survival upon stress (11, 53, 54). Our results demonstrate that ribosomal RACK1 promoted the activity of ECMV IRES (Supplemental Figure 6, C and E), and the possibility that IRES-mediated translation is involved in the progrowth and pro-survival effect of ribosomal RACK1 cannot be excluded. Our data demonstrated that ribosomal RACK1 modulated tumor growth in vivo (Figure 3, A–D), which could possibly in part be explained by the regulatory effect of ribosomal RACK1 on the translation and expression of the potent growth factors cyclin D1 and MYC (Figure 6, A–C). Moreover, since TUNEL staining indicated that the DE mutant xenografts displayed a higher basal rate of apoptosis than other 2 groups (though not statistically significant), it is likely that enhanced tumor cell apoptosis in vivo was also involved in the growth defect of the DE mutant xenografts (Figure 3, C–F). Whether ribosomal RACK1 modulates cellular survival of HCC in vivo needs further investigation.

eIF4E is a potent oncogene whose activity correlates with the phosphorylation on serine 209; phosphorylated eIF4E promotes tumorigenesis primarily by suppressing apoptosis (55). Previous research has demonstrated that the phosphorylation of eIF4E on serine 209 is tightly regulated by MAPK/ERK/MNK signaling (42) and that MNK1 and MNK2 are essential for constitutive and inducible phosphorylation of eIF4E in mice (46). This is also observed in our results: *Mnk1*^{-/-}*Mnk2*^{-/-} MEFs displayed undetectable levels of phosphorylation of eIF4E (Figure 5, I and J). However, transfection of PKC β II restored the phosphorylation of eIF4E in *Mnk1*^{-/-}*Mnk2*^{-/-} MEFs, suggesting PKC β II also as a physiological kinase for eIF4E in vivo (Figure 5I). We assumed that MNKs are predominant kinases for eIF4E under normal conditions, and, with the elevation of RACK1 expression and/or PKC β II activity, eIF4E might become more accessible to RACK1/PKC β II complex as a substrate. It should also be noted that the undetectable expression of PKC β II is observed in several kinds of cell lines (56) as well as in the *Mnk1*^{-/-}*Mnk2*^{-/-} MEFs (Figure 5, I and J), and how RACK1 acts on the translational machinery other than through PKC β II is unknown and needs further investigation. In addition to phosphorylation, eIF4E is also regulated at the level of availability controlled by AKT/mTOR/4E-BP pathway (43), which plays a pivotal role in pathogenesis of HCC (57). Though RACK1 has been reported to be involved in the regulation of ERK and AKT activation (58–60), introduction of RACK1 in HCC exhibited little effect on ERK/MNK and AKT/4E-BP phosphorylation (Supplemental Figure 9 and our unpublished observations). Our results suggest that aberrant expression of RACK1 in HCC contributes to vigorous protein synthesis through functioning on ribosome, and the underlying mechanism that regulates the binding of RACK1 to ribosome needs further investigation.



Currently, there is no standard treatment for unresectable HCC. Transarterial chemoembolization, which is widely used in non-surgical cases, shows benefits in survival for patients with preserved liver function and absence of extrahepatic spread (61, 62). In recent years, sorafenib, a multikinase inhibitor that blocks Raf signaling as well as that of VEGF, PDGF, and c-kit, has shown antiproliferative and antiangiogenic activity and increased the median overall survival from 7.9 to 10.7 months (63, 64). Moreover, among patients with advanced HCC, treatment with sorafenib plus doxorubicin, compared with doxorubicin monotherapy, resulted in greater median time to progression, overall survival, and progression-free survival (65). Therefore, it has great potential in developing new agents and strategies for this group of patients. Our data suggest RACK1 as a new biomarker to establish the risk and prognosis of HCC and to help in the selection of therapeutic modalities in clinical practice and propose a strategy to target RACK1 as a potential adjuvant therapy in combination with other methods for HCC treatment.

Methods

Patients and tissue samples. Tumor tissues from 162 primary HCC cases, surgically resected at Huashan Hospital of Fudan University (Shanghai, China), were fixed in 10% formalin and embedded in paraffin. Fresh HCC tissues and their peripheral nontumor tissues after surgical resection were collected from patients with primary HCC at Nantong Tumor Hospital (Nantong University, Jiangsu, China). None of the patients received clinical treatment before surgery. The frozen normal tissues were also collected in the Nantong Tumor Hospital (Nantong University, Jiangsu, China).

Cell lines and reagents. See the Supplemental Methods for details.

Real-time PCR analysis. See the Supplemental Methods for details.

Plasmid construction, RNA interference, and virus packaging. The human RACK1 cDNA was a gift from Jean-Luc Parent (Université de Sherbrooke, Sherbrooke, Québec, Canada). See Supplemental Methods for more details.

Evaluation of cell apoptosis. See the Supplemental Methods for details.

Oligo-dT pull-down. Oligo-dT pull-down assay was performed as described previously (36). Briefly, equal amounts of transfected cells were collected and lysed in hypotonic buffer, and lysates were incubated with oligo-dT tablets (Invitrogen) for 1 hour at room temperature. After incubation, mixtures were pelleted, washed, resuspended in Laemmli buffer, and analyzed.

Coinmunoprecipitation and GST pull-down assay. See the Supplemental Methods for details.

M²GDP affinity chromatography. See the Supplemental Methods for details.

TAT-peptide delivery. The plasmid expressing TAT-RACK1 peptide (TAT-RP) was constructed by inserting the coding sequence of RACK1 (aa 94–136), which mimics the binding site of RACK1 for PKCβII, into pET22b-PTD vector, as described previously (21). The plasmid expressing TAT-control peptide (TAT-CP) was constructed by inserting the coding sequence of RACK1 (aa 270–317), which is not required for RACK1 binding to PKCβII, into pET22b-PTD. Recombinant proteins were expressed in *Escherichia coli* BL21 cells and purified using an Ni-NTA agarose column (Qiagen). For suppressing RACK1/PKCβII interaction, Huh7 cells were treated with the TAT peptides at the concentration of 10 μg/ml for 4 hours before further analysis.

[³⁵S]-methionine incorporation assay. See the Supplemental Methods for details.

Polysome profiles. Polysome profiling was carried out as described previously (36). Briefly, Huh7 cells were harvested and lysed in lysis buffer (5 mM Tris-HCl [pH 7.4], 4 mM MgCl₂, 1.5 mM KCl, 1 mM DTT, 1% Tri-

ton X-100, 0.5% sodium deoxycholate) in the presence of 100 μg/ml cycloheximide. The lysates were clarified, loaded onto 10%–50% sucrose gradients, and ultracentrifuged. For Western blot analysis, equal volumes of fractions were precipitated with trichloroacetic acid. For real-time PCR analysis, RNA was isolated as described previously (66). Briefly, individual fractions were digested with proteinase K, followed by phenol/chloroform extraction, and total RNA was recovered by ethanol precipitation. Equal volumes of RNA from each fraction were used to generate cDNA, followed by real-time PCR analysis.

In vitro phosphorylation assay. See the Supplemental Methods for details.

Luciferase activity assay. See the Supplemental Methods for details.

The MNK1/2 double-knockout MEFs. The MNK1/2 double-knockout mice were gifts from Rikiro Fukunaga (Osaka University, Osaka, Japan) and have been described previously (46). MEFs were prepared from 13.5-days postcoitus embryos as described previously (67).

Tumor xenograft experiments. See the Supplemental Methods for details.

Immunohistochemical staining and scoring. See the Supplemental Methods for details.

TUNEL assay. See the Supplemental Methods for details.

Statistics. Results are presented as mean ± SD. Differences between 2 groups were tested using Student's 2-tailed *t* test. One-way ANOVA was used for comparison of multiple groups. Two-way repeated-measures ANOVA was used to assess the statistical significance of 2-factor interactions. Pearson's correlation analysis was used to determine the correlation between RACK1 and cyclin D1, MYC, Survivin, or BCL-2. Survival data were analyzed with Kaplan-Meier test. Statistical significance was determined at the level of *P* < 0.05.

Study approval. The use of human tissue samples and clinical data was approved by the ethics committee of Fudan University. All donors were informed of the aim of the study and gave consent to donate their samples. Animal experiments were performed according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals, prepared by the National Academy of Sciences and published by the National Institutes of Health, and also approved by the ethics committee of Fudan University.

Acknowledgments

We thank Jean-Luc Parent (Université de Sherbrooke, Sherbrooke, Québec, Canada) for the human RACK1 cDNA. We thank Rikiro Fukunaga (Osaka University, Osaka, Japan) for the MNK1/2 DKO mice. We thank Songwen Zhang (Fudan University, Shanghai, China) for fruitful discussions and comments on the manuscript. This work was supported by grants from the National Basic Research Program of China (973 Program) (2010CB912104, 2011CB910604, 2012CB8221004, 2011CB710800), the National High-tech R&D Program (863 Program) (2012AA020203), the State Key Project Specialized for Infectious Diseases of China (2012ZX10002-008, 2012ZX10002-012), and National Natural Science Fund (30900266, 30930025, 31000348, 31000600, 31010103906, 31170766, 11179012).

Received for publication April 13, 2011, and accepted in revised form April 24, 2012.

Address correspondence to: Jianxin Gu, Gene Research Center, Shanghai Medical College of Fudan University, PO Box 103, Shanghai 200032, People's Republic of China. Phone: 86.21.54237704; Fax: 86.21.64437703; E-mail: jxgu@shmu.edu.cn.

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: globocan 2000. *Int J Cancer*. 2001;94(2):153–156.

2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. *Lancet*. 2003;362(9399):1907–1917.

3. Bruix J, Sherman M. Management of hepatocellular carcinoma. *Hepatology*. 2005;42(5):1208–1236.

4. Okada S. Chemotherapy in hepatocellular carcinoma. *Hepatogastroenterology*. 1998;45(suppl 3):1259–1263.



5. Kawai S, et al. Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. *Semin Oncol*. 1997;24(suppl 6):S6-38-S6-45.
6. Ruggero D, Pandolfi PP. Does the ribosome translate cancer? *Nat Rev Cancer*. 2003;3(3):179-192.
7. Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. *Nat Rev Cancer*. 2010;10(4):254-266.
8. Sonenberg N, Pause A. Signal transduction. Protein synthesis and oncogenesis meet again. *Science*. 2006;314(5798):428-429.
9. Kapp LD, Lorsch JR. The molecular mechanics of eukaryotic translation. *Annu Rev Biochem*. 2004;73:657-704.
10. Gebauer F, Hentze MW. Molecular mechanisms of translational control. *Nat Rev Mol Cell Biol*. 2004;5(10):827-835.
11. Holcik M, Sonenberg N. Translational control in stress and apoptosis. *Nat Rev Mol Cell Biol*. 2005;6(4):318-327.
12. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. *Oncogene*. 2004;23(18):3189-3199.
13. Mamane Y, et al. Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. *PLoS One*. 2007;2(2):e242.
14. Graff JR, et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. *J Clin Invest*. 2007;117(9):2638-2648.
15. Meric F, Hunt KK. Translation initiation in cancer: a novel target for therapy. *Mol Cancer Ther*. 2002;1(11):971-979.
16. Tam KH, Yang ZF, Lau CK, Lam CT, Pang RW, Poon RT. Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. *Cancer Lett*. 2009;273(2):201-209.
17. Mondesire WH, et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. *Clin Cancer Res*. 2004;10(20):7031-7042.
18. Bordeleau ME, et al. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. *J Clin Invest*. 2008;118(7):2651-2660.
19. Cencic R, Carrier M, Trnkas A, Porco JA Jr, Minden M, Pelletier J. Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells. *Leuk Res*. 2010;34(4):535-541.
20. Ron D, Chen CH, Caldwell J, Jamieson L, Orr E, Mochly-Rosen D. Cloning of an intracellular receptor for protein kinase C: a homolog of the beta subunit of G proteins. *Proc Natl Acad Sci U S A*. 1994;91(3):839-843.
21. McCahill A, Warwicker J, Bolger GB, Houslay MD, Yarwood SJ. The RACK1 scaffold protein: a dynamic cog in cell response mechanisms. *Mol Pharmacol*. 2002;62(6):1261-1273.
22. Link AJ, et al. Direct analysis of protein complexes using mass spectrometry. *Nat Biotechnol*. 1999;17(7):676-682.
23. Sengupta J, Nilsson J, Gursky R, Spahn CM, Nissen P, Frank J. Identification of the versatile scaffold protein RACK1 on the eukaryotic ribosome by cryo-EM. *Nat Struct Mol Biol*. 2004;11(10):957-962.
24. Baum S, Bittins M, Frey S, Seedorf M. Asc1p, a WD40-domain containing adaptor protein, is required for the interaction of the RNA-binding protein Sep160p with polysomes. *Biochem J*. 2004;380(pt 3):823-830.
25. Berns H, Humar R, Hengerer B, Kiefer FN, Battagay EJ. RACK1 is up-regulated in angiogenesis and human carcinomas. *FASEB J*. 2000;14(15):2549-2558.
26. Wang Z, et al. RACK1, an excellent predictor for poor clinical outcome in oral squamous carcinoma, similar to Ki67. *Eur J Cancer*. 2009;45(3):490-496.
27. Nagashio R, et al. Expression of RACK1 is a novel biomarker in pulmonary adenocarcinomas. *Lung Cancer*. 2010;69(1):54-59.
28. Cao XX, et al. RACK1: A superior independent predictor for poor clinical outcome in breast cancer. *Int J Cancer*. 2010;127(5):1172-1179.
29. Myklebust LM, Akslen LA, Varhaug JE, Lillehaug JR. Receptor for activated protein C kinase 1 (RACK1) is overexpressed in papillary thyroid carcinoma. *Thyroid*. 2011;21(11):1217-1225.
30. Zhang W, et al. RACK1 and CIS mediate the degradation of BimEL in cancer cells. *J Biol Chem*. 2008;283(24):16416-16426.
31. Lopez-Bergami P, Habelhah H, Bhoomik A, Zhang W, Wang LH, Ronai Z. RACK1 mediates activation of JNK by protein kinase C [corrected]. *Mol Cell*. 2005;19(3):309-320.
32. Kiely PA, Baillie GS, Lynch MJ, Houslay MD, O'Connor R. Tyrosine 302 in RACK1 is essential for insulin-like growth factor-I-mediated competitive binding of PP2A and beta1 integrin and for tumor cell proliferation and migration. *J Biol Chem*. 2008;283(34):22952-22961.
33. Kiely PA, et al. Phosphorylation of RACK1 on tyrosine 52 by c-Abl is required for insulin-like growth factor I-mediated regulation of focal adhesion kinase. *J Biol Chem*. 2009;284(30):20263-20274.
34. Mamidipudi V, Zhang J, Lee KC, Cartwright CA. RACK1 regulates G1/S progression by suppressing Src kinase activity. *Mol Cell Biol*. 2004;24(15):6788-6798.
35. Arimoto K, Fukuda H, Imajoh-Ohmi S, Saito H, Takekawa M. Formation of stress granules inhibits apoptosis by suppressing stress-responsive MAPK pathways. *Nat Cell Biol*. 2008;10(11):1324-1332.
36. Ceci M, et al. Release of eIF6 (p27BBP) from the 60S subunit allows 80S ribosome assembly. *Nature*. 2003;426(6966):579-584.
37. Shor B, Calaycay J, Rushbrook J, McLeod M. Cpc2/RACK1 is a ribosome-associated protein that promotes efficient translation in *Schizosaccharomyces pombe*. *J Biol Chem*. 2003;278(49):49119-49128.
38. Gerbasi VR, Weaver CM, Hill S, Friedman DB, Link AJ. Yeast Asc1p and mammalian RACK1 are functionally orthologous core 40S ribosomal proteins that repress gene expression. *Mol Cell Biol*. 2004;24(18):8276-8287.
39. Hao Y, et al. CDK1p46 and RPS8 associate with each other and suppress translation in a synergistic manner. *Biochem Biophys Res Commun*. 2011;407(1):169-174.
40. Nilsson J, Sengupta J, Frank J, Nissen P. Regulation of eukaryotic translation by the RACK1 protein: a platform for signalling molecules on the ribosome. *EMBO Rep*. 2004;5(12):1137-1141.
41. Ron D, Jiang Z, Yao L, Vagts A, Diamond I, Gordon A. Coordinated movement of RACK1 with activated beta1IPKC. *J Biol Chem*. 1999;274(38):27039-27046.
42. Pyronnet S, Imataka H, Gingras AC, Fukunaga R, Hunter T, Sonenberg N. Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. *EMBO J*. 1999;18(1):270-279.
43. Haghighat A, Mader S, Pause A, Sonenberg N. Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E. *EMBO J*. 1995;14(22):5701-5709.
44. Marcotrigiano J, Gingras AC, Sonenberg N, Burley SK. Crystal structure of the messenger RNA 5' cap-binding protein (eIF4E) bound to 7-methyl-GDP. *Cell*. 1997;89(6):951-961.
45. Rabl J, Leibundgut M, Aitade SF, Haag A, Ban N. Crystal structure of the eukaryotic 40S ribosomal subunit in complex with initiation factor 1. *Science*. 2011;331(6018):730-736.
46. Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. *Mol Cell Biol*. 2004;24(15):6539-6549.
47. Gausdal G, et al. Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death. *Blood*. 2008;111(5):2866-2877.
48. Robert F, Carrier M, Rawe S, Chen S, Lowe S, Pelletier J. Altering chemosensitivity by modulating translation elongation. *PLoS One*. 2009;4(5):e5428.
49. Xu J, et al. Hepatitis B virus X protein blunts senescence-like growth arrest of human hepatocellular carcinoma via reducing Notch1 cleavage. *Hepatology*. 2010;52(1):142-154.
50. Wei Y, et al. Identification of beta-1,4-galactosyltransferase I as a target gene of HBx-induced cell cycle progression of hepatoma cell. *J Hepatol*. 2008;49(6):1029-1037.
51. Liu H, et al. Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway. *Cancer Res*. 2011;71(24):7547-7557.
52. Ohn T, Kedersha N, Hickman T, Tisdale S, Anderson P. A functional RNAi screen links O-GlcNAc modification of ribosomal proteins to stress granule and processing body assembly. *Nat Cell Biol*. 2008;10(10):1224-1231.
53. Holcik M, Sonenberg N, Korneluk RG. Internal ribosome initiation of translation and the control of cell death. *Trends Genet*. 2000;16(10):469-473.
54. Graber TE, Holcik M. Cap-independent regulation of gene expression in apoptosis. *Mol Biosyst*. 2007;3(12):825-834.
55. Wendel HG, et al. Dissecting eIF4E action in tumorigenesis. *Genes Dev*. 2007;21(24):3232-3237.
56. Metzger E, et al. Phosphorylation of histone H3T6 by PKCbeta(1) controls demethylation at histone H3K4. *Nature*. 2010;464(7289):792-796.
57. Villanueva A, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. *Gastroenterology*. 2008;135(6):1972-1983.
58. Vomastek T, Iwanicki MP, Schaeffer HJ, Tarcsafalvi A, Parsons JT, Weber MJ. RACK1 targets the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway to link integrin engagement with focal adhesion disassembly and cell motility. *Mol Cell Biol*. 2007;27(23):8296-8305.
59. Cao XX, et al. RACK1 promotes breast carcinoma proliferation and invasion/metastasis in vitro and in vivo. *Breast Cancer Res Treat*. 2010;123(2):375-386.
60. Wang F, Yamauchi M, Muramatsu M, Osawa T, Tsuchida R, Shibuya M. RACK1 regulates VEGF/Flt1-mediated cell migration via activation of a PI3-K/Akt pathway. *J Biol Chem*. 2011;286(11):9097-9106.
61. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. *Cancer Cell*. 2004;5(3):215-219.
62. Forner A, Real MI, Varela M, Bruix J. Transarterial chemoembolization for patients with hepatocellular carcinoma. *Hepatol Res*. 2007;37(suppl 2):S230-S237.
63. Liu L, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. *Cancer Res*. 2006;66(24):11851-11858.
64. Llovet JM, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med*. 2008;359(4):378-390.
65. Abou-Alfa GK, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. *JAMA*. 2010;304(19):2154-2160.
66. Marash L, et al. DAP5 promotes cap-independent translation of Bcl-2 and CDK1 to facilitate cell survival during mitosis. *Mol Cell*. 2008;30(4):447-459.
67. Kamijo T, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. *Cell*. 1997;91(5):649-659.